On March 17, 2022, the Board of Directors (the Board) of Emergent BioSolutions Inc. (the Company) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022 (the Effective Date), with an initial term expiring at the 2022 annual meeting of stockholders. He was also appointed as a member of both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board, as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.19 USD | -1.12% | +8.60% | +157.92% |
02/05 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
02/05 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+157.92% | 324M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. Appoints Keith Katkin as a Class I Director, Member of Both the Nominating and Corporate Governance Committee and Strategic Operations Committee of the Board